Adult T-cell leukemia/lymphoma: A pending challenge

• Autores: Álvarez, Carolina, Beltran , Brady
• Formato: artículo
• Fecha de Publicación: 2024
• Institución: Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Repositorio: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
• Lenguaje: español
• OAI Identifier: oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2189
• Enlace del recurso: https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2189
• Nivel de acceso: acceso abierto
• Materia: Virus Linfotrópico T Tipo 1 Humano; Leucemia-Linfoma de Células T del Adulto; Epidemiología; Protocolos Antineoplásicos; Human T-lymphotropic virus 1 (HTLV-1); Leukemia-Lymphoma; Adult T-lymphoma (ATLL); Epidemiology; Antineoplastic Protocols

Adult T-cell leukemia/lymphoma (ATLL) is a post timic T-cell neoplasia of poor prognosis and difficult management. It has been etiologically associated with Human T-lymphotropic virus 1 (HTLV-1), a retrovirus that has been identified in endemic regions such as Japan, Western Africa, the Caribbean islands and South America. In Perú, it is estimated that 1-2% of the population carries the virus. The lifetime risk for an HTLV-1 carrier to develop ATLL is 5%. Given the endemicity of this infection in our setting and the poor overall prognosis of ATLL, there is a need for novel therapeutic strategies and preventive interventions. In this review, we explore the clinical and epidemiological characteristics of ATLL and its therapeutic options.